New Alzheimer’s Therapy Shows Promise with Single-Injection Immunotherapy

The fight against Alzheimer’s disease has reached a pivotal moment, with emerging therapies demonstrating the ability to slow cognitive decline. While current monoclonal antibody treatments offer a degree of benefit, they require frequent infusions. Now, researchers are exploring innovative approaches, including a novel cellular immunotherapy that could potentially offer a more convenient and effective solution with a single injection.

The Challenge of Alzheimer’s and Amyloid Plaques

Alzheimer’s disease is characterized by the accumulation of amyloid beta protein in the brain, forming plaques that disrupt brain function and lead to cognitive decline 1. Normally, the brain’s immune cells, microglia, help clear cellular waste, but in Alzheimer’s, these cells become overwhelmed 3. Existing treatments, like the recently approved monoclonal antibodies lecanemab and aducanumab, function by lowering amyloid levels, but require ongoing intravenous infusions 1, 4.

Reprogramming Astrocytes to Clear Amyloid

Researchers at Washington University School of Medicine in St. Louis have developed an experimental cellular immunotherapy that aims to address these limitations. Inspired by CAR-T cell therapy used in cancer treatment, the team focused on astrocytes – the most abundant cells in the brain – to create “CAR-astrocytes” 3. These astrocytes are genetically engineered with a chimeric antigen receptor (CAR) that allows them to specifically target and remove amyloid beta plaques 3.

Promising Results in Mouse Models

The study, published in Science on March 5, demonstrated encouraging results in mice predisposed to Alzheimer’s disease. When administered before plaque formation, the CAR-astrocytes prevented plaques from developing. In mice that already had significant plaque buildup, the therapy reduced amyloid plaque levels by approximately 50% 3.

Potential Advantages of a Single-Injection Therapy

Unlike current antibody treatments, this immunotherapy has the potential to be administered as a single injection, offering a significant convenience for patients. Researchers have filed a patent for their CAR-astrocyte engineering method 3. While acknowledging that the therapy is most effective in the earlier stages of the disease – consistent with antibody treatments – the single-injection aspect represents a key potential advantage.

Future Directions and Broader Applications

The research team is continuing to refine the CAR-astrocyte therapy, focusing on optimizing targeting precision and minimizing potential disruption to normal brain cell activity 3. Beyond Alzheimer’s disease, the technology could potentially be adapted to treat other neurological disorders and even brain tumors by modifying the CAR to recognize different markers 3.